BC-4-55 | 827036-76-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: BC-4-55
• 英文别名: 4-Dimethylamino-N-[5-(2-mercapto-acetylamino)-pentyl]-benzamide；Benzamide, 4-(dimethylamino)-N-[5-[(mercaptoacetyl)amino]pentyl]-；4-(dimethylamino)-N-[5-[(2-sulfanylacetyl)amino]pentyl]benzamide
• CAS: 827036-76-0
• 化学式: C₁₆H₂₅N₃O₂S
• 分子量: 323.459
• InChiKey: SGOHSANPZHQNKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  62.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-(5-amino-pentyl)-2-tritylsulfanyl acetamide 在 三乙基硅烷 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 生成 BC-4-55
  参考文献：
  名称：

  Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors

  摘要：

  A series of mercaptoacetamides were designed and synthesized as novel histone deacetylase inhibitors with the aid of modeling. Their ability to inhibit HDAC activity and their effects on cancer cell growth were investigated. Some compounds exhibit better HDAC inhibitory activity than SAHA. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.006

文献信息

• [EN] HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASES ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
  申请人：UNIV ILLINOIS

  公开号：WO2017040564A1

  公开（公告）日：2017-03-09

  Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed

  组蛋白去乙酰化酶抑制剂（HDACIs）及其包含该抑制剂的组合物被公开。还公开了治疗疾病和状况的方法，其中抑制HDAC可带来益处，例如癌症、神经退行性疾病、周围神经病变、神经系统疾病、创伤性脑损伤、中风、高血压、疟疾、自身免疫疾病、孤独症、孤独症谱系障碍和炎症。
• Histone deacetylase inhibitors and methods of use thereof
  申请人：Kozikowski P. Alan

  公开号：US20050032831A1

  公开（公告）日：2005-02-10

  One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

  这项发明的一个方面涉及HDAC抑制剂。还提供了一种使癌细胞对放疗的细胞毒作用敏感的方法。该发明还提供了治疗癌症和治疗神经疾病的方法。此外，该发明还提供了包含该发明的HDAC抑制剂的药物组合物，以及包含一个容器，其中含有该发明的HDAC抑制剂的试剂盒。
• [EN] TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS<br/>[FR] ACIDES HYDROXAMIQUES SUBSTITUÉS PAR TÉTRAHYDROQUINOLINE EN TANT QU'INHIBITEURS SÉLECTIFS DE L'HISTONE DÉSACÉTYLASE 6
  申请人：UNIV ILLINOIS

  公开号：WO2017142883A1

  公开（公告）日：2017-08-24

  Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.

  组揭示了组蛋白去乙酰化酶抑制剂（HDACIs）及含有其的组合物。还揭示了治疗疾病和病况的方法，其中抑制HDAC能够带来益处，如癌症、神经退行性疾病、神经疾病、创伤性脑损伤、中风、疟疾、自身免疫疾病、自闭症和炎症。
• GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF
  申请人：HEYMAN Norman S.

  公开号：US20130029924A1

  公开（公告）日：2013-01-31

  Glycosylated valproic acid and its analogs are provided. In some embodiments, the glycosylated valproic acid and its analogs have improved solubility and are ideal for drug delivery to treat a variety of diseases.

  提供了糖基化的丙戊酸及其类似物。在某些实施方式中，糖基化的丙戊酸及其类似物具有改善的溶解性，并且非常适合用于药物输送以治疗各种疾病。
• [EN] BICYCLIC AND TRICYCLIC CAP BEARING MERCAPTOACETAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] DÉRIVÉS BICYCLIQUES ET TRICYCLIQUES DE MERCAPTOACÉTAMIDE COIFFÉS A TITRE D'INHIBITEURS D'HISTONES DÉSACÉTYLASES
  申请人：UNIV ILLINOIS

  公开号：WO2017053360A1

  公开（公告）日：2017-03-30

  Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.

  揭示了组蛋白去乙酰化酶抑制剂（HDACIs）及含有其的组合物。还揭示了治疗疾病和病况的方法，其中抑制HDAC提供益处，如癌症、神经退行性疾病、周围神经病变、神经系统疾病、创伤性脑损伤、中风、高血压、疟疾、自身免疫疾病、自闭症、自闭症谱系障碍和炎症。